[HTML][HTML] Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations
Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …
A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor
S Abhyankar, S DeJarnette, O Aljitawi… - Bone Marrow …, 2012 - nature.com
Autologous hematopoietic stem cell (HSC) transplant is an effective treatment for patients
with hematological malignancies. Unfortunately, 15–30% of patients fail to mobilize a …
with hematological malignancies. Unfortunately, 15–30% of patients fail to mobilize a …
Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU …
RF Duarte, BE Shaw, P Marin, P Kottaridis… - Bone Marrow …, 2011 - nature.com
Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the
European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for …
European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for …
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with …
MJ Dugan, RT Maziarz, WI Bensinger… - Bone marrow …, 2010 - nature.com
Plerixafor, a novel CXCR4 inhibitor, is effective in mobilizing PBSCs particularly when used
in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor …
in conjunction with G-CSF. In four cohorts, this pilot study explored the safety of plerixafor …
Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma
GM Keating - Drugs, 2011 - Springer
Plerixafor (Mozobil®) is a CXCR4 chemokine receptor antagonist that is indicated for use in
combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the …
combination with granulocyte colony-stimulating factor (G-CSF) to mobilize stem cells to the …
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
JF DiPersio, EA Stadtmauer… - Blood, The Journal …, 2009 - ashpublications.org
Abstract This phase 3, multicenter, randomized (1: 1), double-blind, placebo-controlled study
evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G …
evaluated the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G …
Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell …
G Tricot, MH Cottler-Fox, G Calandra - Bone Marrow Transplantation, 2010 - nature.com
This was an open-label, single-center, phase II study of 20 patients with multiple myeloma
who were either proven poor mobilizers (n= 10; group A) or predicted poor mobilizers (n …
who were either proven poor mobilizers (n= 10; group A) or predicted poor mobilizers (n …
[HTML][HTML] Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34+ hematopoietic stem …
AP Nademanee, JF DiPersio, RT Maziarz… - Biology of Blood and …, 2012 - Elsevier
Preapheresis peripheral blood (PB) CD34+ cell count is a strong predictor of hematopoietic
stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success …
stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success …
[HTML][HTML] Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic …
Collection of adequate hematopoietic stem cells (HSCs) is necessary for successful
autologous transplantation; however, a proportion of patients fail to collect the minimum …
autologous transplantation; however, a proportion of patients fail to collect the minimum …
How I treat patients who mobilize hematopoietic stem cells poorly
LB To, JP Levesque, KE Herbert - Blood, The Journal of the …, 2011 - ashpublications.org
Abstract Transplantation with 2-5× 106 mobilized CD34+ cells/kg body weight lowers
transplantation costs and mortality. Mobilization is most commonly performed with …
transplantation costs and mortality. Mobilization is most commonly performed with …